NLRP1 Is a Prominent Inflammasome Sensor Found in Bronchial Epithelial Cells in Asthma and Can Be Activated by Rhinovirus A16

Keywords: Asthma, inflammasome, NLRP1, rhinovirus, bronchial epithelial cells, chronic inflammatory diseases, microRNA, asthma exacerbations, therapeutic approaches, clinical research   Summary:   In this podcast episode, Professor Ana Rebane discusses her recent research on the NLRP1 inflammasome sensor in bronchial epithelial cells and its implications for asthma pathogenesis. She shares insights into her research background, the significance of NLRP1 in asthma exacerbations, and the surprising results from her in vitro studies. The conversation also touches on future research directions, potential therapeutic approaches for asthma, and the experience of publishing in Clinical and Experimental Allergy.   Takeaways NLRP1 is a prominent inflammasome sensor in asthma. Research focuses on RNA-mediated regulations in chronic inflammatory diseases. NLRP1 is a main target of rhinovirus during infections. The study highlights the complexity of inflammatory sensors in asthma. In vitro studies revealed unexpected results regarding NLRP1 activation. Targeting inflammasome pathways may be crucial for asthma treatment. The research utilized bronchial brushing specimens for accurate modeling. Surprising findings suggest other viruses may activate different pathways. Future research should explore various viruses and their inflammasome impacts. Publishing in Clinical and Experimental Allergy was a positive experience. Titles Exploring NLRP1: A Key Player in Asthma The Role of Inflammasomes in Asthma Pathogenesis   Chapters   00:00 Introduction to the Podcast and Guest 00:59 Professor Anna Rebane's Research Background 02:46 Understanding NLRP1 in Asthma Pathogenesis 05:21 Methodology and In Vitro Studies 07:39 Surprising Findings in Inflammasome Pathways 08:39 Implications for Future Research and Therapeutics 10:23 Publishing Experience and Conclusion

Om Podcasten

Summary This conversation highlights the significant contributions of the Clinical and Experimental Allergy (CEA) journal to the field of allergy research and clinical practice. The hosts and Editors-In-Chief discuss the journal’s achievements, including advancements in allergy diagnosis, innovative treatments, and a focus on patient-centric research. They also outline future directions for the journal, emphasising collaboration and accessibility in allergy research. Takeaways - CEA is a leading publication in allergy and immunology. - The journal publishes groundbreaking research on allergy mechanisms. - Innovative diagnostic methods are a focus of CEA’s contributions. - Promising new treatments, including biologics, are showcased. - Food allergy research informs better management practices. - Environmental factors influencing allergies are examined. - Patient-reported outcomes are prioritised in research. - The journal’s Impact Factor has reached a record high. - Future plans include enhancing author support and engagement. - Collaboration with patient organisations is a key focus for CEA.